Controversy coverage

RegulationWatch

Original reporting on regulatory enforcement, PBM conduct and governance failures across the US pharmaceutical industry.

RedFlag Index™ · Leader · November 2026
Score 87 · #1 controversy exposure
9 documented cases · 5 open
View full ranking →
  1. 340B Program

    Missouri orders Eli Lilly to drop 340B claims-data condition after hospital cut-off

    Missouri Attorney General Catherine Hanaway sent Eli Lilly a cease-and-desist letter alleging its requirement that 340B hospitals hand over claims data violates state consumer protection law. Lilly had cut University of Missouri Health Care off from 340B pricing in July.

  2. PBM Oversight

    House Oversight chair investigates whether PBMs used audits to punish pharmacies that backed reform

    Chairman James Comer asked CVS Caremark, Express Scripts and Optum Rx for documents and briefings after independent pharmacies that supported H.R. 6610 reported a surge of burdensome audits. The companies have not been accused in any proceeding.

  3. False Claims Act

    DOJ and HHS open six-month window for healthcare companies to self-disclose False Claims Act violations

    A new pilot lets healthcare companies, including drug manufacturers, resolve previously unknown False Claims Act exposure by repaying 1.25 to 1.6 times the base amount. Participants avoid exclusion, corporate integrity agreements and civil monetary penalties.

  4. Drug Pricing

    Pennsylvania sues the three largest insulin makers and PBMs over alleged pricing scheme

    Pennsylvania Attorney General Dave Sunday sued Eli Lilly, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark and OptumRx under the state's consumer protection law. Because Pennsylvania has no general antitrust statute, the case relies on deception claims rather than price-fixing law.

  5. Controlled Substances Act

    CVS agrees to pay $315 million to settle federal opioid dispensing case

    The Justice Department announced that CVS Pharmacy will pay $315 million to resolve Controlled Substances Act and False Claims Act allegations that it filled unlawful opioid prescriptions and billed federal programs for them. CVS admitted no liability and signed a compliance agreement with the DEA.

  6. Opioid Litigation

    Arizona sues Express Scripts and Optum, alleging rebate deals helped drive the opioid epidemic

    Arizona Attorney General Kris Mayes filed a consumer fraud lawsuit alleging the two pharmacy benefit managers secured confidential payments from opioid manufacturers, including Purdue Pharma, in exchange for preferred formulary status and fewer utilization controls. Optum called the suit misdirected.

  7. Antitrust

    Forty-five states seek approval of generic price-fixing settlements with Ascend, Mayne and Citron

    A 45-state coalition asked the court to approve settlements with three more generic manufacturers in the long-running price-fixing litigation. The monetary terms total $1.05 million; the larger cases against Teva, Sandoz and others continue.

  8. Drug Promotion

    Pfizer markets Vyndamax as the "only once-daily capsule". The evidence says otherwise.

    Patients are not informed that a cheaper rival pill exists, or that Pfizer paid the support group it recommends.

  9. Drug Pricing

    Public order discloses reversal of $48 million award against OptumRx

    A Florida federal court publicly released an order vacating a $48,362,033 arbitration award against OptumRx entities. The underlying decision was dated September 17.

  10. PBM Rebates

    Express Scripts settled the insulin case without paying a cent or admitting a thing.

    The FTC's order changes how Cigna's pharmacy benefit manager behaves from here. It returns nothing for the years the agency says list prices were inflated.

  11. Antitrust

    States seek approval of Sandoz settlement worth approximately $469 million

    State attorneys general sought approval of a generic-drug pricing settlement with Sandoz and Fougera. Illinois described approximately $469 million in total obligations, including $69 million for previously settling states.

  12. False Claims Act

    A jury found 3.3 million false claims at CVS's Omnicare. The $948.8 million judgment is settling for $440 million.

    Omnicare filed for bankruptcy two months after the judgment. The government now stands to collect less than half, and CVS admits nothing.

  13. State Enforcement

    Florida sues Pfizer and Albert Bourla over vaccine marketing

    Florida filed a consumer-protection lawsuit against Pfizer and its chief executive. Pfizer disputed the allegations.

  14. Opioid Litigation

    McKesson is paying up to $7.4 billion over opioid distribution, and admits nothing.

    The largest distributor's share of the national settlement runs for 18 years. None of it goes to individual patients.

  15. Drug Pricing

    CMS finalises international benchmark model for Medicare Part B drugs

    CMS finalised the GLOBE drug-payment model, with initial reporting in January 2027 and its performance period beginning April 2027. The rule is a payment-policy measure, not an enforcement finding against manufacturers.

  16. PBM Rebates

    Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.

    Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.

  17. Antitrust

    Caremark wins partial dismissal while Rxeed interference claim survives

    A New York federal judge dismissed Rxeed's antitrust and contractual-interference claims against Caremark. A claim concerning prospective business relationships remains pending.

  18. False Claims Act

    Dompé funded the charities that paid its own drug's copays. It cost $32 million.

    The company reported itself and got credit for it. The admissions it signed show how the arrangement was built around the launch of Oxervate.

  19. Drug Pricing

    Fruth reimbursement claims move to arbitration and Missouri federal court

    A West Virginia federal judge ordered arbitration of Fruth's claims against OptumRx and Caremark. Claims against Express Scripts were severed and transferred to Missouri.